中文摘要：

目的：探讨右佐匹克隆替换对长期服用苯二氮[艹卓]类药的慢性精神分裂症患者睡眠的影响。方法：采用开放式设计,依照医师和患者协商结果将80例长期服用苯二氮[艹卓]类药的慢性精神分裂症住院患者分成右佐匹克隆组（41例,在1周内逐渐换用右佐匹克隆3 mg/d）和对照组（39例,服用的苯二氮[艹卓]类药品及剂量不变）;观察4周。替换前后分别给予匹兹堡睡眠质量指数量表（PSQI）、阳性和阴性症状量表（PANSS）及治疗中出现的症状量表（TESS）评定及比较。结果：替换前后两组间PSQI评分差异无统计学意义;替换后右佐匹克隆组PSQI总分及睡眠质量、入睡时间、睡眠时间和日间功能障碍评分明显低于替换前（F=31.69,7.03,4.79,10.58;P〈0.05或P〈0.01）;替换前后两组PANSS评分比较差异无统计学意义;右佐匹克隆组药物不良反应发生率（6.25%）低于对照组（23.75%）,差异有统计学意义（P〈0.05）。结论：应用右佐匹克隆替换,可改善长期服用的苯二氮[艹卓]类药慢性精神分裂症患者的睡眠质量和日间功能;安全可行。

英文摘要：

Objective：To study the efficacy and safety of dexzopiclone replacement treatment for sleep in patients with chronic schizophrenia current in long-term benzodiazepine use. Method：Open trial design was used in current study. Inpatient with chronic schizophrenia current in long-term benzodiazepines use were divided into two groups based on the decision both of patients and their psychiatrists. In the dexzopiclone group, benzodiazepines was gradually withdrawn within one week, and the same time, dexzopiclone was titrated to 3 mg/dand followed up to 4 weeks. In the control group, benzodiazepines were used as before. The Pittsburgh sleep quality index（PSQI） was used to evaluate the quality of sleep, the positive and negative symptoms scale （PANSS） was used to assess the severity of symptom, and the treatment emergent symptom scale （TESS） was used to assess the treatment safety. Results： There was no significant difference in the score of PSQI and PANSS between the two groups either at the baseline or the end of study. In the dexzopiclone group, the PSQI sub-scale showed that the daytime dysfunction, sleep time, sleep quality and sleep disorder symptoms were improved significantly （F =31.69, 7. 03, 4. 79, 10. 58 ;P 〈0.05 or P 〈0.01 ）. The incidence of adverse effect （6.25%） in the tdexzopiclone group was obviously lower than the control group （23.75%） （P 〈 0.05 ）. Conclusion：Dexzopiclone replacement treatment could improve sleep quality and daytime function in patients with chronic schizophrenia current in long-term benzodiazepine use. Considering the low risk of adverse effect, dexzopiclone is worthy to try in clinical practice.